AlphaProteo is the first AI system launched by DeepMind designed to create novel, high-affinity protein complexes as building blocks for biological and health research. This technology has the potential to accelerate our understanding of biological processes and support drug discovery and biosensor development. AlphaProteo can generate new protein complexes for a variety of target proteins, including VEGF-A, which is associated with cancer and diabetes complications. It outperforms existing methods in terms of experimental success rates and binding affinity, significantly reducing the time needed for preliminary experiments involving protein complexes.